ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd (ENLV)

1.32
0.05
(3.94%)
Closed April 23 4:00PM
1.32
0.00
( 0.00% )
Pre Market: 4:04AM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.32
Bid
1.32
Ask
1.39
Volume
1
0.00 Day's Range 0.00
1.15 52 Week Range 4.59
Market Cap
Previous Close
1.32
Open
-
Last Trade
1
@
1.38
Last Trade Time
04:36:52
Financial Volume
-
VWAP
-
Average Volume (3m)
178,556
Shares Outstanding
18,420,000
Dividend Yield
-
PE Ratio
-0.78
Earnings Per Share (EPS)
-1.69
Revenue
-
Net Profit
-31.06M

About Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threate... Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Ness Ziona, Center, Isr
Founded
1970
Enlivex Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ENLV. The last closing price for Enlivex Therapeutics was $1.32. Over the last year, Enlivex Therapeutics shares have traded in a share price range of $ 1.15 to $ 4.59.

Enlivex Therapeutics currently has 18,420,000 shares outstanding. The market capitalization of Enlivex Therapeutics is $24.31 million. Enlivex Therapeutics has a price to earnings ratio (PE ratio) of -0.78.

ENLV Latest News

Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis

Nes-Ziona, Israel, April 22, 2024 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

Yet Another Biotech Stock Has Found Success During Tuesday's Session

It appears to be the day for biotechs as yet another company in the space has caught our attention during Tuesday’s session. Earlier in the day, an Illinois-based biotech To read the full...

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Nes-Ziona, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Analysis of eligible1 patients from the sepsis Phase II study (NCT# NCT04612413) In accordance with the study protocol, the safety and efficacy topline analysis includes sequential organ failure...

Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method

Nes-Ziona, Israel, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Second study of Allocetra in knee osteoarthritis, following the on-going Phase I/II trial in pre-surgery, end-stage osteoarthritis, that is continuing to enroll patients Nes-Ziona, Israel, Jan...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.19-12.5827814571.511.561.23011381031.41731817CS
4-2.57-66.06683804633.894.591.153763712.08522997CS
12-1.42-51.82481751822.744.591.151785562.52557092CS
260.010.7633587786261.314.591.151281372.56006332CS
52-1.59-54.63917525772.914.591.15754832.51740262CS
156-8.88-87.058823529410.213.951.15864446.79259354CS
260-7.19-84.48883666278.5144.91.151583419.87370029CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.2448
(60.74%)
3.68M
ZPTAZapata Computing Holdings Inc
$ 2.05
(31.41%)
1.32M
TKNOAlpha Teknova Inc
$ 2.21
(22.85%)
393
USCBUSCB Financial Holdings Inc
$ 12.80
(21.33%)
489
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 6.51
(20.78%)
1.14M
EVOEvotec SE
$ 5.33
(-30.33%)
11.9k
TSLZT Rex 2X Inverse Tesla Daily Target ETF
$ 44.25
(-20.87%)
97.31k
TSDDGraniteShares ETF Trust GraniteShares
$ 28.27
(-20.37%)
9.14k
BJDXBluejay Diagnostics Inc
$ 0.50
(-20.00%)
800
KPRXKiora Pharmaceuticals Inc
$ 0.4666
(-19.48%)
6.66k
CYNCYNGN Inc
$ 0.1242
(8.95%)
4.26M
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.2448
(60.74%)
3.68M
PEGYPineapple Energy Inc
$ 0.0599
(5.83%)
2.19M
ZPTAZapata Computing Holdings Inc
$ 2.05
(31.41%)
1.32M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 6.51
(20.78%)
1.14M

ENLV Discussion

View Posts
Monksdream Monksdream 4 weeks ago
ENLV under $4
👍️0
TrendTrade2016 TrendTrade2016 1 month ago
ENLV...NEXT BIO BEAST READY TO break out
👍️0
MOCKBA MOCKBA 5 years ago
I see ok, they should send a PR about it!
👍️0
dinogreeves dinogreeves 5 years ago
I mean that ENLV is now Nasdaq compliant, there are no issues with Nasdaq on their filings,
👍️0
MOCKBA MOCKBA 5 years ago
What you mean by that?
👍️0
dinogreeves dinogreeves 5 years ago
ENLV Nasdaq compliant now, should get a press release soon.
👍️0
dinogreeves dinogreeves 5 years ago
checkout website you'll be impressed

https://www.enlivex.com
👍️0
MOCKBA MOCKBA 5 years ago
Dino, grabbed a small position, looks very intriguing to say the least
👍️0
dinogreeves dinogreeves 5 years ago
They have over 35 million in cash man, no dilution for at least 2 years. Buy ENLV with everything you got.
👍️0
dinogreeves dinogreeves 5 years ago
This is ENLV now, buy all you can, they reverse merged with ORPN
👍️0
dinogreeves dinogreeves 5 years ago
This is one the best bios out there, soon to surpass what BPTH did
👍️0
whytestocks whytestocks 5 years ago
News: $ORPN Bioblast Announces Effectiveness of Eight to One Reverse Split

Tel Aviv, Israel, March 06, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the effectiveness of an eight to one reverse split of its share capital. As previously reported, the reverse split was approv...

Find out more https://marketwirenews.com/news-releases/bioblast-announces-effectiveness-of-eight-to-one-reverse-split-7810132.html
👍️0
ClayTrader ClayTrader 5 years ago
* * $ORPN Video Chart 02-19-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 years ago
* * $ORPN Video Chart 11-20-18 * *

Link to Video - click here to watch the technical chart video

👍️0
r1aviator r1aviator 5 years ago
$ORPN

Bioblast Pharma Ltd. Announces Entry Into Merger Agreement to Acquire Enlivex Therapeutics Ltd. to Advance Clinical Stage Immunotherapeutic Drug Pipeline for the Treatment of Life-Threatening Diseases Sepsis, GvHD and Solid Tumors

https://twitter.com/birdseyepix/status/1064655592529117184?s=21
👍️0
r1aviator r1aviator 5 years ago
Running :)

$ORPN
👍️0
r1aviator r1aviator 6 years ago
Took a starter

$ORPN
👍️0
ClayTrader ClayTrader 6 years ago
* * $AXXA Video Chart 05-18-18 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 6 years ago
* * $SDRL Video Chart 05-18-18 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 6 years ago
* * $ORPN Video Chart 05-18-18 * *

Link to Video - click here to watch the technical chart video

👍️0
europtiger europtiger 6 years ago
Crazy downer but buying more 3,10 as i belive Shorts will bien there Fingers
👍️0
europtiger europtiger 6 years ago
Looking good

Nice bids coming in

👍️0
crudeoil24 crudeoil24 6 years ago
Very nice call! Blast off > Blast Pharma! orpn
👍️0
europtiger europtiger 6 years ago
Here we Go
👍️0
europtiger europtiger 6 years ago
Yep float has been traded allready

Hope for breakout just bought more

But stop is in
👍️0
crudeoil24 crudeoil24 6 years ago
Traders running this low floater > Brooklyn!
👍️0
europtiger europtiger 6 years ago
Got 2,90‘s
👍️0
Golden Cross Golden Cross 6 years ago
ORPN cheat sheet:

https://www.barchart.com/stocks/quotes/ORPN/cheat-sheet
👍️0
Golden Cross Golden Cross 6 years ago
Short squeeze info:


http://shortsqueeze.com/?symbol=orpn&submit=Short+Quote%E2%84%A2
👍️0
Golden Cross Golden Cross 6 years ago
MACD looking bullish
👍️0
Golden Cross Golden Cross 6 years ago
Chart shaping up:

👍️0
DewDiligence DewDiligence 6 years ago
Caveat emptor! This looks like a financing deal is coming soon.
👍️0
europtiger europtiger 6 years ago
Running hard

Super Low Float
👍️0
Me stocks Me stocks 6 years ago
This one is investment. It will go to 15$ at least in 2018.
👍️0
Awl416 Awl416 6 years ago
That was fast
👍️0
DewDiligence DewDiligence 6 years ago
ORPN 9/30/17 cash=$4.1M (down from $5.2M at 6/30/17):

https://finance.yahoo.com/news/bioblast-pharma-reports-third-quarter-113000168.html
👍️0
DewDiligence DewDiligence 7 years ago
1:5 reverse split is effective today (eom).
👍️0
DewDiligence DewDiligence 7 years ago
ORPN implements 1:5 reverse split effective on date to be announced:

https://www.sec.gov/Archives/edgar/data/1596812/000114420417048497/v475345_6k.htm
👍️0
jcbaby jcbaby 7 years ago
you are correct this play could rise very very fast
👍️0
theprofit444 theprofit444 7 years ago
its a revised outlook lmaooooo
👍️0
jcbaby jcbaby 7 years ago
didn't you say 10 awhile back lol lets hope for anything but its current price
👍️0
theprofit444 theprofit444 7 years ago
itll be 4 dollars a share by yr end
👍️0
DewDiligence DewDiligence 7 years ago
ORPN 2Q17 PR:

https://www.sec.gov/Archives/edgar/data/1596812/000114420417040598/v472433_ex99-1.htm

6/30/17 cash was $5.2M.
👍️0
jcbaby jcbaby 7 years ago
this could rocket over a dollar in a swift blow got to be ready
👍️0
DewDiligence DewDiligence 7 years ago
Two months has elapsed since the post I'm replying to. They'd better come up with a plan soon.
👍️0
stocktrademan stocktrademan 7 years ago
ORPN buy 0.656

inverted head and shoulders bottom
bullish divergence breakout and initial pullback level
high volume on advances, lower volume on retracements indicates strong demand for the stock
pennant breakout soon
breaking out over the ichimoku cloud
moving average golden cross pattern









normal chart




log chart



👍️0
jcbaby jcbaby 7 years ago
should be an interesting day for this stock will see?
👍️0
ClayTrader ClayTrader 7 years ago
* * $ORPN Video Chart 06-30-17 * *

Link to Video - click here to watch the technical chart video

👍️0
Klinsmann Klinsmann 7 years ago
Indeed! On a day it made nearly 100% off of its lows...
👍️0
jr525 jr525 7 years ago
Awfully quiet in here
👍️0

Your Recent History

Delayed Upgrade Clock